These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32801163)

  • 1.
    Kim LC; Rhee CH; Chen J
    Mol Cancer Res; 2020 Nov; 18(11):1675-1684. PubMed ID: 32801163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
    Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
    Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin and mTORC2 inhibition synergistically reduce contraction-stimulated muscle protein synthesis.
    Ogasawara R; Knudsen JR; Li J; Ato S; Jensen TE
    J Physiol; 2020 Dec; 598(23):5453-5466. PubMed ID: 32893874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
    Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
    Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
    Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras
    Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B
    Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
    Julien LA; Carriere A; Moreau J; Roux PP
    Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD146 Regulates Growth Factor-Induced mTORC2 Activity Independent of the PI3K and mTORC1 Pathways.
    Xu W; Hua H; Chiu YH; Li G; Zhi H; Yu Z; Ren F; Luo Y; Cui W
    Cell Rep; 2019 Oct; 29(5):1311-1322.e5. PubMed ID: 31665642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
    Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
    Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR hyperactivity and
    Sztankovics D; Moldvai D; Petővári G; Dankó T; Szalai F; Miyaura R; Varga V; Nagy N; Papp G; Pápay J; Krencz I; Sebestyén A
    Pathol Oncol Res; 2024; 30():1611643. PubMed ID: 38515456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
    Gulhati P; Cai Q; Li J; Liu J; Rychahou PG; Qiu S; Lee EY; Silva SR; Bowen KA; Gao T; Evers BM
    Clin Cancer Res; 2009 Dec; 15(23):7207-16. PubMed ID: 19934294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
    Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
    Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts.
    Hong-Brown LQ; Brown CR; Navaratnarajah M; Huber DS; Lang CH
    Alcohol Clin Exp Res; 2011 Aug; 35(8):1445-53. PubMed ID: 21438886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
    Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
    Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
    García-Martínez JM; Alessi DR
    Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTORC2 acts as a gatekeeper for mTORC1 deficiency-mediated impairments in ILC3 development.
    Deng YF; Wu ST; Peng HY; Tian L; Li YN; Yang Y; Meng M; Huang LL; Xiong PW; Li SY; Yang QL; Wang LL; Li XY; Li LP; Lu XL; Li XH; Wei YL; Xiao ZH; Yu JH; Deng YC
    Acta Pharmacol Sin; 2023 Nov; 44(11):2243-2252. PubMed ID: 37407703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.